Sarcomas are soft tissue tumors with limited treatment options, which often include radiation therapy. For some sarcomas, the benefit of radiation is limited, and enhancing its effect could improve patient outcomes.
Our research has focused on radiosensitization: increasing the sensitivity of tumors to radiation. We do this via administration of drugs that enrich tumor cells in more vulnerable stages of their cell cycles. We are currently developing MITX-101, a radiosensitizing drug which we will test in a clinical trial for glioblastoma in 2026.
The ENRICH-SARCOMA projectteam intends to study the potential for MITX-101 in preclinical sarcoma models in cell lines and mice, to identify several types of sarcoma for which this could be a promising therapeutic strategy. If this project demonstrates preclinical benefit, it is possible that MITX-101 could provide a low-burden add-on to improve treatment options for patients.
We already have a depth of experience working with MITX-101, and therefore a substantial supply of drug, and appropriate preparatory documentation to proceed to clinical use, making preclinical and clinical testing very efficient. In addition to the important data generated in this project on the potential for MITX-101 in sarcoma, we will also generate regulatory and development data and documents that will accelerate the progress to potentially helping sarcoma patients.
